Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile

Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer

Open label, single dose and phase I study.

The primary objective: To determine the maximum tolerated dose in Single dose

The secondary objective: to evaluate the toxicity in administration to determine desirable dosing amount for phase II to evaluate tumor response in progressive solid cancer patients to evaluate pharmacokinetic/ pharmacodynamic profile.

1. Number of Subjects: 28~36, dose escalation (2~6 subject of each step)
2. Adverse Events will be coded to preferred therm and body system using the CTCAE

Inclusion Criteria:

• from 20 years old to 69 years old
• diagnosed with progressive solid cancer
• In spite of standard chemotherapies, the efficacy of the treatment or life extension cannot be expected.
• Evaluated 0-1 of ECOG
• Expected life duration is within 3 months

Exclusion Criteria:

• Major surgery except tumor-removal surgery received within 2 weeks of screening.
• history of CNS metasis
• hyper-sensitivy of study drug
• pregancy or lactating
• administered other HDAC inhibitor within 4 weeks of screening